DK3472314T3 - Fremstilling af faktor-xa-derivater - Google Patents

Fremstilling af faktor-xa-derivater Download PDF

Info

Publication number
DK3472314T3
DK3472314T3 DK17814267.5T DK17814267T DK3472314T3 DK 3472314 T3 DK3472314 T3 DK 3472314T3 DK 17814267 T DK17814267 T DK 17814267T DK 3472314 T3 DK3472314 T3 DK 3472314T3
Authority
DK
Denmark
Prior art keywords
derivatives
factor
preparation
Prior art date
Application number
DK17814267.5T
Other languages
English (en)
Inventor
Mark Karbarz
Pamela B Conley
Genmin Lu
Original Assignee
Alexion Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60663351&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3472314(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alexion Pharma Inc filed Critical Alexion Pharma Inc
Application granted granted Critical
Publication of DK3472314T3 publication Critical patent/DK3472314T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6432—Coagulation factor Xa (3.4.21.6)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/20—Partition-, reverse-phase or hydrophobic interaction chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Enzymes And Modification Thereof (AREA)
DK17814267.5T 2016-06-17 2017-06-19 Fremstilling af faktor-xa-derivater DK3472314T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662351841P 2016-06-17 2016-06-17
PCT/US2017/038169 WO2017219034A2 (en) 2016-06-17 2017-06-19 Preparation of factor xa derivatives

Publications (1)

Publication Number Publication Date
DK3472314T3 true DK3472314T3 (da) 2021-07-26

Family

ID=60663351

Family Applications (1)

Application Number Title Priority Date Filing Date
DK17814267.5T DK3472314T3 (da) 2016-06-17 2017-06-19 Fremstilling af faktor-xa-derivater

Country Status (23)

Country Link
US (4) US10604748B2 (da)
EP (2) EP3472314B1 (da)
JP (3) JP6959268B2 (da)
KR (1) KR102373215B1 (da)
CN (2) CN116425860A (da)
AU (2) AU2017283720B2 (da)
BR (1) BR112018075964A2 (da)
CA (1) CA3027457A1 (da)
CL (2) CL2018003654A1 (da)
CO (1) CO2019000120A2 (da)
DK (1) DK3472314T3 (da)
EA (1) EA037815B1 (da)
ES (1) ES2875538T3 (da)
HU (1) HUE054597T2 (da)
IL (1) IL263591B2 (da)
MX (1) MX2018015873A (da)
PE (1) PE20190661A1 (da)
PH (1) PH12018502614A1 (da)
PL (1) PL3472314T3 (da)
PT (1) PT3472314T (da)
SG (1) SG11201810915QA (da)
SI (1) SI3472314T1 (da)
WO (1) WO2017219034A2 (da)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2414517B1 (en) * 2009-03-30 2016-09-21 Portola Pharmaceuticals, Inc. Antidotes for factor xa inhibitors and methods of using the same
SG10201705189XA (en) * 2013-01-24 2017-07-28 Portola Pharm Inc INHIBITION OF TISSUE FACTOR PATHWAY INHIBITOR WITH FACTOR Xa DERIVATIVES
AU2017283720B2 (en) * 2016-06-17 2022-11-17 Alexion Pharmaceuticals, Inc. Preparation of factor Xa derivatives
EP3810187A4 (en) * 2018-06-19 2022-08-31 Alexion Pharmaceuticals, Inc. ANTIDOTES FOR FACTOR XA INHIBITORS
KR102337683B1 (ko) * 2018-09-21 2021-12-13 주식회사 녹십자 고효율 항-tfpi 항체 조성물

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5189019A (en) 1990-04-23 1993-02-23 Merck & Co., Inc. Antistasin derived anticoagulant protein
US5589571A (en) * 1994-10-28 1996-12-31 Cor Therapeutics, Inc. Process for production of inhibited forms of activated blood factors
JPH1066572A (ja) * 1996-08-29 1998-03-10 Showa Sangyo Co Ltd 高純度の大豆トリプシンインヒビターの製造方法
ES2254385T3 (es) 2000-02-29 2006-06-16 Millennium Pharmaceuticals, Inc. Benzamidas e inhibidores relacionados del factor xa.
ATE549317T1 (de) 2005-11-08 2012-03-15 Millennium Pharm Inc Pharmazeutische salze und polymorphe aus n-(5- chloro-2-pyridinyl)-2-ää4- ä(dimethylamino)iminomethylübenzoylüaminoü-5- methoxy-benzamid, einem faktor-xa-hemmer
BRPI0816837B1 (pt) 2007-09-28 2022-10-18 Portola Pharmaceuticals, Inc Composições farmacêuticas, polipeptídeo isolado de duas cadeias e uso de uma composição farmacêutica
KR101649770B1 (ko) 2008-11-14 2016-08-19 포톨라 파마슈티컬스, 인코포레이티드 인자 ｘａ 저해제에 대한 해독제 및 혈액 응고제와 조합된 그의 사용 방법
EP2414517B1 (en) 2009-03-30 2016-09-21 Portola Pharmaceuticals, Inc. Antidotes for factor xa inhibitors and methods of using the same
US9056106B2 (en) 2009-07-15 2015-06-16 Portola Pharmaceuticals, Inc. Unit dose formulation of antidotes for factor Xa inhibitors and methods of using the same
KR102210574B1 (ko) * 2012-06-14 2021-02-01 포톨라 파마슈티컬스, 인코포레이티드 재조합 인자 Xa 유도체의 정제방법
US20140346397A1 (en) * 2012-12-27 2014-11-27 Portola Pharmaceuticals, Inc. Compounds and methods for purification of serine proteases
SG10201705189XA (en) 2013-01-24 2017-07-28 Portola Pharm Inc INHIBITION OF TISSUE FACTOR PATHWAY INHIBITOR WITH FACTOR Xa DERIVATIVES
AU2014326257B2 (en) * 2013-09-24 2017-08-10 Pfizer Inc. Compositions comprising heterogeneous populations of recombinant human clotting factor Xa proteins
CN107073082B (zh) * 2014-08-20 2021-04-30 博尔托拉制药公司 Xa因子解毒剂的冻干制剂
AU2017283720B2 (en) * 2016-06-17 2022-11-17 Alexion Pharmaceuticals, Inc. Preparation of factor Xa derivatives

Also Published As

Publication number Publication date
CN110167575B (zh) 2024-03-15
US20210348149A1 (en) 2021-11-11
AU2017283720A1 (en) 2019-01-03
HUE054597T2 (hu) 2021-09-28
IL263591B (en) 2022-11-01
EA201990052A1 (ru) 2019-05-31
EP3472314A2 (en) 2019-04-24
IL263591A (en) 2019-02-03
AU2017283720B2 (en) 2022-11-17
CL2020001733A1 (es) 2020-09-25
US10604748B2 (en) 2020-03-31
JP2023086970A (ja) 2023-06-22
SI3472314T1 (sl) 2021-11-30
PE20190661A1 (es) 2019-05-08
CA3027457A1 (en) 2017-12-21
JP2019528242A (ja) 2019-10-10
JP6959268B2 (ja) 2021-11-02
AU2023200825A1 (en) 2023-03-16
KR20190019134A (ko) 2019-02-26
EP3472314B1 (en) 2021-05-05
JP2022000477A (ja) 2022-01-04
KR102373215B1 (ko) 2022-03-10
CL2018003654A1 (es) 2019-01-25
PH12018502614A1 (en) 2019-09-30
CN110167575A (zh) 2019-08-23
US20200208131A1 (en) 2020-07-02
US11845966B2 (en) 2023-12-19
EP3472314A4 (en) 2020-01-22
US20240076642A1 (en) 2024-03-07
JP7273918B2 (ja) 2023-05-15
ES2875538T3 (es) 2021-11-10
BR112018075964A2 (pt) 2019-04-02
IL263591B2 (en) 2023-03-01
US20170369862A1 (en) 2017-12-28
MX2018015873A (es) 2019-08-12
CO2019000120A2 (es) 2019-03-29
EA037815B1 (ru) 2021-05-25
CN116425860A (zh) 2023-07-14
EP3926044A1 (en) 2021-12-22
WO2017219034A2 (en) 2017-12-21
PL3472314T3 (pl) 2021-11-22
WO2017219034A3 (en) 2019-03-14
PT3472314T (pt) 2021-06-18
US10954504B2 (en) 2021-03-23
SG11201810915QA (en) 2019-01-30

Similar Documents

Publication Publication Date Title
DK3512850T3 (da) Inhibitorer af menin-mll-interaktionen
DK3468966T3 (da) Inhibitorer af menin-mll-interaktionen
DK3137169T3 (da) Hæmmere af lysin-specifik demethylase-1
DK3302565T3 (da) Faste doseringsformer af palbociclib
DK3201410T3 (da) Forbedringer af bygningsbeklædninger
DK3554240T3 (da) Kombinationer af aktive forbindelser
DK3178817T3 (da) Amorf form af tetracyklisk forbindelse
DK3457851T3 (da) Derivater af sobetirom
DK3180331T3 (da) Polymorfer af selinexor
DK3509581T3 (da) Formuleringer af (r)-2-amino-3-phenylpropylcarbamat
DK2845905T3 (da) Fremstilling af oligosaccharider
DK3157508T3 (da) Fast oral doseringsform af lipofile forbindelser
DK3448846T3 (da) Syntese af indazoler
DK3798222T3 (da) Krystallinsk form af den frie base af lorlatinib
DK3448849T3 (da) Syntese af indazoler
DK3472314T3 (da) Fremstilling af faktor-xa-derivater
DK3307267T3 (da) Behandling af multipel sklerose
DK3294532T3 (da) Forbedringer i forbindelse med fremstilling af vindmøllekomponenter
DK3094322T3 (da) Administration af tasimelteon i fastende tilstand
DK3220891T3 (da) Sublingual formulering af riluzol
DK3368044T3 (da) Behandling af hepatisk steatose-relateret oligo-ovulation
DK3201323T3 (da) Modificering af bakteriofag
DK3297619T3 (da) Terapeutiske anvendelser af L-4-chlorkynurenin
DK3328395T3 (da) Ny brug af dextransulfat
DK3529236T3 (da) Krystalformer af eravacyclin